Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | ERN1 | O75460 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28467263 | 1.00 | PDE4A (0.52) | PDE4AERN1ALDH1A1TSHRTDP1 | |
| SCHEMBL8840880 | 0.84 | PDE4A (0.67) | PDE4AERN1ALDH1A1TSHRTDP1 | |
| SCHEMBL5329103 | 0.84 | PDGFRB (0.47) | ALDH1A1TSHRTDP1CYP3A4HSD17B10 | |
| SCHEMBL3987934 | 0.82 | ALDH1A1 (0.44) | ERN1ALDH1A1TSHRCYP3A4HSD17B10 | |
| SCHEMBL28764944 | 0.82 | CYP17A1 (0.54) | ERN1ALDH1A1PDGFRBPDGFRAKDM4E | |
| SCHEMBL695680 | 0.82 | CYP17A1 (0.54) | ERN1ALDH1A1PDGFRBPDGFRAKDM4E | |
| SCHEMBL28947822 | 0.82 | MAOB (0.52) | ALDH1A1TDP1HSD17B10MAPTHPGD | |
| SCHEMBL9020733 | 0.82 | HPGD (0.41) | PDE4AALDH1A1TDP1CYP3A4PDGFRB | |
| SCHEMBL8461866 | 0.81 | PDE4A (0.65) | PDE4A | |
| SCHEMBL5326742 | 0.80 | ALDH1A1 (0.54) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853207-B2 | Heterocyclic pyrazole compounds, method for preparing the same and use thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-10-07 | — | — | US | claimed |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-10-17 | — | — | US | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | NOVARTIS AG | 2009-10-15 | — | — | US | claimed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| US-6962942-B2 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-11-08 | — | — | US | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| EP-1212300-B1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2003051879-A1 | KNOWN AND NOVEL 4,5-DIHYDRO-IMIDAZO[4,5,1-IJ]QUINOLIN-6-ONES USEFUL AS POLY(ADP-RIBOSE)POLYMERASE INHIBITORS | ALTANA PHARMA AG (DE) | 2003-06-26 | — | — | WO | claimed |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-12 | — | — | US | claimed |
| US-6469029-B1 | INHIBITORS OF THROMBIN PRODUCTION VIA FACTOR XA INHIBITION; COUPLED TO MEDICAL DEVICES, SUCH AS STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-22 | — | — | US | claimed |
| EP-1212300-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | claimed |
| CN-105541662-B | The solid phase synthesis process of dihydro naphthalene compounds | 云南大学 | 2018-04-17 | — | — | CN | disclosed |
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| WO-2001019795-A1 | AZACYCLOALKANONE SERINE PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0360701-A1 | Antifungal compounds containing amides and phenyl groups | RHONE-POULENC AGROCHIMIE (FR) | 1990-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258882-A1 | 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIK3CA | PDE4A 947/4885ERN1 1291/4885ALDH1A1 1849/4885 |
| US-20130274255-A1 | HETEROCYCLIC PYRAZOLE COMPOUNDS, METHOD FOR PREPARING THE SAME AND USE THEREOF | RET, FLT3, FGFR1 | PDE4A 1683/4885ERN1 1939/4885ALDH1A1 1491/4885 |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | PDE4A 732/4885ERN1 2890/4885ALDH1A1 4394/4885 |
| US-20030109517-A1 | Azacycloalkanone serine protease inhibitors | CTRL, SERPINE1, SERPINB1 | PDE4A 4148/4885ERN1 543/4885ALDH1A1 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.